AstraZeneca to invest $2bn in Summit for ADC combination therapies
AstraZeneca has agreed to invest $2bn in newly issued equity in Summit Therapeutics to develop combination therapies using the bispecific antibody ivonescimab and ADCs across multiple tumour types.
Read the full article on the original site.
Read Full Article